References
- Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-270. https://doi.org/10.1016/0360-3016(92)90740-9
- Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008;22:1267-1278, x. https://doi.org/10.1016/j.hoc.2008.08.012
- Ji JH, Yun T, Kim SB, Kang JH, Park JC, Cho IS, et al. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer(KCSG HN07-01). Eur J Cancer. 2012;48:3198-204. https://doi.org/10.1016/j.ejca.2012.06.009
- Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008;118:663-670. https://doi.org/10.1097/MLG.0b013e3181626cfe
- Lin H, Cai X, Jin T, Guo L, Wang H, Sun R, et al. Chemotherapy plus radiotherapy makes curability a possibility in nasopharyngeal carcinoma patients with distant metastasis at diagnosis. Head Neck Oncol. 2013;5:1.
- Lin S, Tham IW, Pan J, Han L, Chen Q, Lu JJ. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol. 2012;35:474-479. https://doi.org/10.1097/COC.0b013e31821a9452
- Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol. 2000;18:1324-1330. https://doi.org/10.1200/JCO.2000.18.6.1324
- Kong L, Hu C, Niu X, Zhang Y, Guo Y, Tham IW, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: Interim results from 2 prospective phase 2 clinical trials. Cancer. In press 2013.
- Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357:1705-1715. https://doi.org/10.1056/NEJMoa070956
- Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study. Ann Oncol. 2004;15:638-45. https://doi.org/10.1093/annonc/mdh145
- Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17:2092-2099. https://doi.org/10.1200/JCO.1999.17.7.2092
- Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol. 2004;22:62-68. https://doi.org/10.1200/JCO.2004.01.021
- Kretschmar C, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam M. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2007;48:285-291. https://doi.org/10.1002/pbc.20815
- Patil V, Noronha V, Joshi A, Muddu Krishna V, Juvekar S, Pantvaidya G, et al. Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy? ISRN Oncol. 2013;2013:259154.
- Fang WJ, Lam KO, Ng SC, Choi CW, Kwong DL, Zheng SS, et al. Manual contouring based volumetric evaluation for colorectal cancer with liver limited metastases: A comparison with RECIST. Asian Pac J Cancer Prev. 2013;14:4151-4155. https://doi.org/10.7314/APJCP.2013.14.7.4151